With $165M In Financing From Novo, Repair Impact Fund To Support Early-Stage Development Of Innovative Antibiotics

Financial Times: Novo to invest $165m in first ‘superbug’ venture fund
“The first venture fund dedicated to investing in companies fighting superbugs resistant to modern drugs is to be launched on Wednesday, with $165m finance from Novo Holdings of Denmark. The Repair Impact Fund aims to put $20m-$40m a year over three to five years into European and U.S. start-ups and early-stage ventures developing innovative antibiotics aimed at bacteria the World Health Organization regards as the greatest threat to human health…” (Cookson, 2/27).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.